Promore Pharma
19.11.2021 13:31:49 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 19, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Promore Pharma AB (publ) publishes its interim report for the third quarter 2021 on 23 November 2021.
The next day, 24 November, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/3513796589233231628
The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2021
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/673758/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-Third-Quarter-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Achieves New Milestone With Semi-Autonomous CCA Flight12.2.2026 21:55:00 CET | Press release
YFQ-42A Uncrewed Fighter Jet Executes Mission Autonomy Test SAN DIEGO, CA / ACCESS Newswire / February 12, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) passed a new milestone this month, successfully integrating 3rd-party mission autonomy into the YFQ-42A Collaborative Combat Aircraft to conduct its first semi-autonomous airborne mission. For this test, GA-ASI used mission autonomy software supplied by Collins Aerospace, an RTX business, to fly the new YFQ-42A CCA, designed and developed by GA-ASI for the U.S. Air Force. The Sidekick Collaborative Mission Autonomy software was seamlessly integrated with the YFQ-42A's flight control system, utilizing the Autonomy Government Reference Architecture (A-GRA). The integration enabled robust and reliable data exchange between the autonomy software and the aircraft's mission systems, ensuring precise execution of mission autonomy commands. During the recent testing, autonomy mode was activated via the Ground Station Console (GSC)
Loar Holdings Inc. Announces Date and Time for Fourth Quarter and Full Year 2025 Earnings Conference Call12.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / February 12, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q4 and Full Year 2025 earnings before the market opens on Thursday, February 26, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center12.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FLORIDA / ACCESS Newswire / February 12, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), announces the reopening of its experiential USPA Shop Flagship at the USPA National Polo Center (NPC) in Wellington, Florida. The sports brand is introducing a reimagined retail destination that reflects the brand's deep connection to the sport of polo and its modern global positioning.The USPA Shop Flagship at the USPA National Polo Center Photo Credit: Augustina Fonda The USPA Shop at NPC now places a strong emphasis on the guest experience. Inside and out, the space is complemented by refined visuals, immersive activations, curated sound, a signature scent, and a best-in-class assortment of apparel and accessories from the brand's design hubs of New York, London, Florence, and Istanbul. The refreshed design of the flagship location blends heritage, sport, and contemporary style, incorporating signature U.S. Polo Assn. elements such
Fidelity Investments Upgrades FINOS Membership to Platinum, Reinforcing Its Strategic Commitment to Open Source Collaboration in Financial Services11.2.2026 15:00:00 CET | Press release
Following its leadership in launching Fluxnova, Fidelity's appointment to the FINOS Governing Board underscores the growing recognition of the ROI of open source for all market participants NEW YORK CITY, NY / ACCESS Newswire / February 11, 2026 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced that Fidelity Investments has upgraded its FINOS membership to Platinum, reflecting Fidelity's deepening strategic commitment to open source collaboration, industry interoperability, and the responsible adoption of emerging technologies such as AI across regulated financial services. The membership upgrade builds directly on Fidelity's role in the formation of Fluxnova, a FINOS-hosted open source orchestration platform created to address critical industry needs around workflow automation, vendor independence, and long-term infrastructure sustainability. Fidelity spearheaded the project's contribution into FINOS, helping establi
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program10.2.2026 21:00:00 CET | Press release
GA-ASI's YFQ-42A Platform to Support Next-Generation Expeditionary Air Operations SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 10, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was competitively selected by the U.S. Marine Corps (USMC) for evaluation in the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft (MUX TACAIR) Collaborative Combat Aircraft (CCA) program. The agreement integrates GA-ASI's expertise in autonomy and uncrewed aircraft systems with a government-provided mission package, usingthe YFQ-42A platform as a surrogate to evaluate integration with crewed fighters. The contract initiates integration of a Marine Corps mission kit into the YFQ-42A surrogate platform for assessment within the Marine Air Ground Task Force (MAGTF). The USMC contract includes the rapid development of autonomy for the government-supplied mission kit - a cost-effective, sensor-rich, software-defined suite capable of delivering kinetic and non-kinetic effects -
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom